Generex Biotechnology Corporation
GNBTQ
OTC PK
| 04/30/2021 | 01/31/2021 | 10/31/2020 | 07/31/2020 | 04/30/2020 | |
|---|---|---|---|---|---|
| Revenue | -95.85% | -- | -87.75% | 1,253.36% | -54.37% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -95.85% | -- | -87.75% | 1,253.36% | -54.37% |
| Cost of Revenue | -43.25% | -36.63% | -82.56% | 1,967.05% | -90.81% |
| Gross Profit | -111.85% | -115.18% | -88.93% | 1,103.11% | 322.33% |
| SG&A Expenses | 41.12% | 48.67% | 171.12% | -51.54% | -38.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.74% | 58.37% | 169.46% | -43.10% | -46.70% |
| Operating Income | -78.03% | -88.15% | -210.27% | 49.04% | 45.42% |
| Income Before Tax | 247.29% | -235.26% | -18.00% | -126.20% | 48.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 247.29% | -235.26% | -18.00% | -126.20% | 48.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 448.51% | -12.01% | 38.48% | -55.84% | -83.99% |
| Net Income | 263.91% | -248.51% | -17.59% | -143.91% | 45.45% |
| EBIT | -78.03% | -88.15% | -210.27% | 49.04% | 45.42% |
| EBITDA | -80.99% | -90.96% | -218.75% | 50.68% | 47.11% |
| EPS Basic | 210.12% | -107.69% | 15.23% | -44.15% | 40.08% |
| Normalized Basic EPS | 218.59% | -112.87% | 15.49% | 60.10% | 15.52% |
| EPS Diluted | 40.22% | -100.00% | 15.23% | -38.07% | 40.08% |
| Normalized Diluted EPS | 196.83% | -112.87% | 15.49% | 60.10% | 15.52% |
| Average Basic Shares Outstanding | 48.88% | 67.86% | 38.77% | 69.22% | -8.91% |
| Average Diluted Shares Outstanding | 82.40% | 67.86% | 38.77% | 69.22% | -8.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
